Log In
BCIQ
Print this Print this
 

Anti Tau mAb

  Manage Alerts
Collapse Summary General Information
Company AC Immune S.A.
DescriptionHuman mAb targeting Tau protein
Molecular Target Microtubule-associated protein tau (tau) (MAPT) (FTDP-17)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerGenentech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$418.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/18/2012

Undisclosed

Undisclosed

$418.0M

Get a free BioCentury trial today